Physician profile
Therese Oconnor
NPI 1114995800
$1,605.67
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $611 · 2020: $225 · 2021: $314 · 2022: $303 · 2023: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $153.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $446.94 | 2019-2022 | |
| Pfizer INC. | $413.43 | 2019-2023 | |
| Novo Nordisk INC | $229.11 | 2019-2022 | |
| Agile Therapeutics, INC. | $138.55 | 2021-2023 | Twirla |
| Mylan Pharmaceuticals INC. | $60.14 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.36 | 2019-2021 | |
| Therapeuticsmd, INC. | $44.64 | 2021-2022 | |
| Hologic Sales and Service, LLC | $39.35 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $29.22 | 2019 | |
| Myovant Sciences INC. | $27.23 | 2022 | |
| Medtronic, INC. | $26.55 | 2021 | |
| Sumitomo Pharma America, INC. | $25.95 | 2023 | Myfembree |
| Boston Scientific Corporation | $16.91 | 2019 | |
| Organon LLC | $15.74 | 2021 | |
| Lupin INC. | $12.25 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $11.26 | 2019 | |
| Avion Pharmaceuticals | $11.04 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$3.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Therese Oconnor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.